Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke

Stroke is a common and often fatal event, and, in survivors, it is accompanied by a high risk of recurrence. Ischemic stroke is associated with abnormal platelet activity and thrombus formation. In addition to their roles in the development of acute thrombi, platelets serve as a bridge for leukocyte...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2010-10, Vol.1207 (1), p.11-17
Main Authors: Franks, Zechariah G., Campbell, Robert A., Weyrich, Andrew S., Rondina, Matthew T.
Format: Article
Language:English
Subjects:
Animals
antiplatelet agents
Blood clots
Blood Platelets - physiology
Brain Ischemia - blood
Brain Ischemia - drug therapy
Drug therapy
Humans
Inflammation - blood
Inflammation - drug therapy
leukocytes
Leukocytes - physiology
Platelet Aggregation Inhibitors - therapeutic use
platelets
Risk Factors
Stroke
Stroke - blood
Stroke - drug therapy
Thromboembolism - blood
Thromboembolism - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stroke is a common and often fatal event, and, in survivors, it is accompanied by a high risk of recurrence. Ischemic stroke is associated with abnormal platelet activity and thrombus formation. In addition to their roles in the development of acute thrombi, platelets serve as a bridge for leukocytes within the vasculature. Myeloid leukocytes are critical mediators of atherosclerosis and atherothrombosis. Interactions between platelets and leukocytes foster an inflammatory and thrombotic milieu that influences lesion progression, facilitates plaque rupture, and triggers thrombus formation and embolization. Accordingly, antiplatelet agents, including aspirin, dipyridamole, and clopidogrel, are recommended therapies for most patients with a history of stroke. In addition to mitigating thrombosis, antiplatelet drugs have direct and indirect effects on inflammation, which may translate to enhanced clinical efficacy.
ISSN:0077-8923
1749-6632
DOI:10.1111/j.1749-6632.2010.05733.x